A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia

January 24, 2014
Jae Park, MD

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.

Clinical Pearls

Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.

  • This phase II trial has 13 patients enrolled and is still accruing
  • Patients in the trial will receive the same dose of vemurafenib that is approved for the treatment of late-stage melanoma
  • Following three cycles of therapy, disease response is assessed, and patients can continue on vemurafenib for three additional cycles